Ophira Michal Ginsburg

Dr. Ophira Michal Ginsburg

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in The Lancet
Verified
Journal Article
Open access
OGOphira Michal Ginsburg
Ophira Michal Ginsburg
FBFreddie Bray
Freddie Bray
MCMichel P Coleman
Michel P Coleman
VVVerna Vanderpuye
Verna Vanderpuye
AEAlexandru Eniu
Alexandru Eniu
LCLesong Conteh
Lesong Conteh
Every year, more than 2 million women worldwide are diagnosed with breast or cervical cancer, yet where a woman lives, her socioeconomic status, and agency largely determines whether she will develop one of these cancers and will ultimately survive. In regions with scarce resources, fragile or fragmented health systems, cancer contributes to the cycle of poverty. Proven and cost-effective interventions are available for both these common cancers, yet for so many women access to these is beyond reach. These inequities highlight the urgent need in low-income and middle-income countries for sustainable investments in the entire continuum of cancer control, from prevention to palliative care, and in the development of high-quality population-based cancer registries. In this first paper of the Series on health, equity, and women's cancers, we describe the burden of breast and cervical cancer, with an emphasis on global and regional trends in incidence, mortality, and survival, and the consequences, especially in socioeconomically disadvantaged women in different settings.

15 May 2020 in Cancer
Verified
Journal Article
Open access
PDF file
OGOphira Michal Ginsburg
Ophira Michal Ginsburg
YCYIP CHENG-HAR
YIP CHENG-HAR
ABAri Brooks
Ari Brooks
ACAnna Cabanes
Anna Cabanes
MCMaira Caleffi
Maira Caleffi
BABenjamin O. Anderson
Benjamin O. Anderson
When breast cancer is detected and treated early, the chances of survival are very high. However, women in many settings face complex barriers to early detection, including social, economic, geographic, and other interrelated factors, which can limit their access to timely, affordable, and effective breast health care services. Previously, the Breast Health Global Initiative (BHGI) developed resource‐stratified guidelines for the early detection and diagnosis of breast cancer. In this consensus article from the sixth BHGI Global Summit held in October 2018, the authors describe phases of early detection program development, beginning with management strategies required for the diagnosis of clinically detectable disease based on awareness education and technical training, history and physical examination, and accurate tissue diagnosis. The core issues address include finance and governance, which pertain to successful planning, implementation, and the iterative process of program improvement and are needed for a breast cancer early detection program to succeed in any resource setting. Examples are presented of implementation, process, and clinical outcome metrics that assist in program implementation monitoring. Country case examples are presented to highlight the challenges and opportunities of implementing successful breast cancer early detection programs, and the complex interplay of barriers and facilitators to achieving early detection for breast cancer in real‐world settings are considered.

13 January 2015 in JAMA
Verified
Journal Article
Open access
PDF file
JIJavaid Iqbal
Javaid Iqbal
OGOphira Michal Ginsburg
Ophira Michal Ginsburg
PRPaula A. Rochon
Paula A. Rochon
PSPing Sun
Ping Sun
Steven NarodSteven Narod
Steven Narod
In the United States, incidence rates of breast cancer among women vary substantially by racial/ethnic group.1-3 The age-adjusted rates for breast cancer are 129 per 100 000 for non-Hispanic white women, 93 per 100 000 for Hispanic women, 123 per 100 000 for black women, and 94 per 100 000 for Asian women.1 There are differences in survival as well; crude 10-year survival rates are 80% for white women, 78% for Hispanic American women, 66% for black women, and 82% for Asian women.4

1 February 2017 in The Lancet
Verified
Journal Article
Closed access
LDLynette Denny
Lynette Denny
SSSilvia de Sanjose
Silvia de Sanjose
MMMiriam Mutebi
Miriam Mutebi
BABenjamin O Anderson
Benjamin O Anderson
JKJane Kim
Jane Kim
RSRengaswamy Sankaranarayanan
Rengaswamy Sankaranarayanan

26 September 2023 in The Lancet
Verified
Journal Article
Closed access
OGOphira Michal Ginsburg
Ophira Michal Ginsburg
VVVerna Vanderpuye
Verna Vanderpuye
ABAnn Marie Beddoe
Ann Marie Beddoe
NBNirmala Bhoo-Pathy
Nirmala Bhoo-Pathy
FBFreddie Bray
Freddie Bray
ISIsabelle Soerjomataram
Isabelle Soerjomataram

9 March 2012 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
Joanne KotsopoulosJoanne Kotsopoulos
Joanne Kotsopoulos
JLJan Lubiński
Jan Lubiński
LSLeonardo Salmena
Leonardo Salmena
HLHenry T Lynch
Henry T Lynch
CKCharmaine Kim-Sing
Charmaine Kim-Sing
TGthe Hereditary Breast Cancer Clinical Study Group
the Hereditary Breast Cancer Clinical Study Group
Introduction: Breastfeeding has been inversely related to breast cancer risk in the general population. Clarifying the role of breastfeeding among women with a BRCA1 or BRCA2 mutation may be helpful for risk assessment and for recommendations regarding prevention. We present an updated analysis of breastfeeding and risk of breast cancer using a large matched sample of BRCA mutation carriers. Methods: We conducted a case-control study of 1,665 pairs of women with a deleterious mutation in either BRCA1 (n = 1,243 pairs) or BRCA2 (n = 422 pairs). Breast cancer cases and unaffected controls were matched on year of birth, mutation status, country of residence and parity. Information about reproductive factors, including breastfeeding for each live birth, was collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate the association between ever having breastfed, as well as total duration of breastfeeding, and the risk of breast cancer. Results: Among BRCA1 mutation carriers, breastfeeding for at least one year was associated with a 32% reduction in risk (OR = 0.68; 95% CI 0.52 to 0.91; P = 0.008); breastfeeding for two or more years conferred a greater reduction in risk (OR = 0.51; 95% CI 0.35 to 0.74). Among BRCA2 mutation carriers, there was no significant association between breastfeeding for at least one year and breast cancer risk (OR = 0.83; 95% CI 0.53 to 1.31; P = 0.43). Conclusions: These data extend our previous findings that breastfeeding protects against BRCA1-, but not BRCA2-associated breast cancer. BRCA mutation carriers should be advised of the benefit of breastfeeding in terms of reducing breast cancer risk.